ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference
Rhea-AI Summary
ProKidney (Nasdaq: PROK), a late clinical-stage cellular therapeutics company specializing in chronic kidney disease (CKD), has announced its participation in two major healthcare conferences in September 2025.
The company will present at the Citi Biopharma Back to School Conference in Boston on September 3 at 10:30am ET, and the Morgan Stanley Global Healthcare Conference in New York on September 8 at 7:00am ET. Both presentations will be in a fireside chat format and available via webcast through ProKidney's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – PROK
In the Aug 27 session, PROK gained 4.62%, reflecting a moderate positive market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WINSTON-SALEM, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in September:
| Citi Biopharma Back to School Conference (Boston) | |
| Date: | Wednesday, September 3, 2025 |
| Time: | 10:30am ET |
| Format: | Fireside Chat |
| Webcast: | Link |
| Morgan Stanley Global Healthcare Conference (New York) | |
| Date: | Monday, September 8, 2025 |
| Time: | 7:00am ET |
| Format: | Fireside Chat |
| Webcast: | Link |
The live webcasts of the fireside chats will be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at www.prokidney.com. Investors interested in one-on-one meetings should contact their banking representatives.
About ProKidney Corp.
ProKidney, a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cellular therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit www.prokidney.com.
Investor Contacts:
ProKidney
Ethan Holdaway
Ethan.Holdaway@prokidney.com
LifeSci Advisors, LLC
Daniel Ferry
Daniel@lifesciadvisors.com
